Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3,562.78% | -214.52% | -178.32% | -173.84% | 111.85% |
| Total Depreciation and Amortization | -10.69% | 31.27% | 13.63% | 1.28% | 34.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.86% | 165.76% | 73.10% | 121.05% | 19.06% |
| Change in Net Operating Assets | 106.54% | 179.68% | 145.99% | 49.94% | -1,316.42% |
| Cash from Operations | -1.89% | -16.68% | -174.03% | -50.90% | -687.57% |
| Capital Expenditure | 132.60% | 126.76% | 73.71% | -36.52% | 34.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -46.46% | 159.47% | 246.00% | -78.04% | 169.74% |
| Cash from Investing | -45.43% | 159.22% | 238.61% | -81.71% | 180.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -86.31% | -- | -99.67% | 69.90% | 103.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.31% | 172.73% | -99.67% | 69.90% | 103.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.49% | 119.41% | -96.02% | -4,101.68% | 47.34% |